Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT860QF)

• DTT Name: LCK tyrosine protein kinase (LCK) DTT Info
• Gene Name: LCK

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[1]

3 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VX-680	DM93YKJ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]
ISIS-CRP	DMQDUG4	Cardiovascular disease	BA00-BE2Z	Phase 1	[2]
JNJ-26483327	DMSQ3AZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]

45 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(4-Phenoxy-phenyl)-quinazolin-4-yl-amine	DMFO8DR	Discovery agent	N.A.	Investigative	[4]
2-(3,4,5-Trihydroxy-benzylidene)-malononitrile	DM1I6SO	Discovery agent	N.A.	Investigative	[5]
3-(4-(o-toluidino)pyrimidin-2-ylamino)benzamide	DMX6ZHQ	Discovery agent	N.A.	Investigative	[6]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[7]
4-(3-Chloro-phenoxy)-6,7-dimethoxy-quinazoline	DMDS2LZ	Discovery agent	N.A.	Investigative	[8]
4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine	DMHANXD	Discovery agent	N.A.	Investigative	[9]
6-o-tolylquinazolin-2-amine	DM4TX9O	Discovery agent	N.A.	Investigative	[10]
A-420983	DM7HSCI	Discovery agent	N.A.	Investigative	[11]
A-641359	DM5JSXI	Discovery agent	N.A.	Investigative	[12]
A-770041	DMP78JY	Discovery agent	N.A.	Investigative	[12]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[13]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[14]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[15]
CEP-5104	DMV43GY	Discovery agent	N.A.	Investigative	[16]
CGP-57380	DMFPOUC	Discovery agent	N.A.	Investigative	[2]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[14]
GW-788388	DMIBUW5	Solid tumour/cancer	2A00-2F9Z	Investigative	[17]
HKI-9924129	DM5LR2B	Gram-positive bacterial infection	1B74-1G40	Investigative	[18]
JNJ-10198409	DM9GDP5	Discovery agent	N.A.	Investigative	[19]
JNJ-28312141	DMCMH7O	Discovery agent	N.A.	Investigative	[20]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[14]
L-779450	DM51B74	Discovery agent	N.A.	Investigative	[21]
LAVENDUSTIN A	DMH3X06	Discovery agent	N.A.	Investigative	[22]
Lck inhibitor	DME4TUQ	Discovery agent	N.A.	Investigative	[23]
NM-PP1	DMS8H5Q	Discovery agent	N.A.	Investigative	[2]
PD-0166326	DMD2CG9	Discovery agent	N.A.	Investigative	[18]
PD-0173952	DMSCQ9U	Discovery agent	N.A.	Investigative	[18]
PD-0173955	DMOZEW9	Discovery agent	N.A.	Investigative	[18]
PD-0173956	DM8RW92	Discovery agent	N.A.	Investigative	[18]
PD-0173958	DMZQ8YV	Discovery agent	N.A.	Investigative	[18]
PD-0179483	DMKO8LE	Discovery agent	N.A.	Investigative	[18]
PMID15546730C2	DMOPUIH	Discovery agent	N.A.	Investigative	[24]
PMID17280833C30	DMXHS4L	Discovery agent	N.A.	Investigative	[25]
PMID17600705C23	DMJFOGW	Discovery agent	N.A.	Investigative	[6]
PMID21855335C19a	DMTKJA9	Discovery agent	N.A.	Investigative	[26]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[14]
Ro31-8220	DMDJLF0	Discovery agent	N.A.	Investigative	[14]
RPR-108518A	DMJ6RZI	Discovery agent	N.A.	Investigative	[8]
STAUROSPORINONE	DMU2H4K	Discovery agent	N.A.	Investigative	[14]
SU 6656	DMF1P6W	Discovery agent	N.A.	Investigative	[2]
TG-100435	DMIR3X2	Discovery agent	N.A.	Investigative	[27]
WH-4-023	DMJS8VQ	Discovery agent	N.A.	Investigative	[28]
Y-c[D-Pen-(3,5-diI)Tyr-GSFC]KR-NH2	DMF7S54	Discovery agent	N.A.	Investigative	[29]
Y-c[D-Pen-(3-I)Tyr-GSFC]KR-NH2	DMW1PSO	Discovery agent	N.A.	Investigative	[29]
ZM-336372	DMD5JYQ	Discovery agent	N.A.	Investigative	[2]

References

• [1] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [2] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
• [3] National Cancer Institute Drug Dictionary (drug id 596693).
• [4] Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2167-70.
• [5] Tyrphostins. 3. Structure-activity relationship studies of alpha-substituted benzylidenemalononitrile 5-S-aryltyrphostins. J Med Chem. 1993 Nov 12;36(23):3556-64.
• [6] N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8.
• [7] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
• [8] he preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: Inhibitors of p56lck and EGF-R tyrosine kinase activity, Bioorg. Med. Chem. Lett. 7(4):417-420 (1997).
• [9] Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
• [10] Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86.
• [11] A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. Bioorg Med Chem Lett. 2004 May 17;14(10):2613-6.
• [12] Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. Bioorg Med Chem Lett. 2006 Jan 1;16(1):118-22.
• [13] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [14] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [15] Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
• [16] Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
• [17] Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orall... J Med Chem. 2006 Apr 6;49(7):2210-21.
• [18] Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
• [19] (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
• [20] JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009 Nov;8(11):3151-61.
• [21] The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.
• [22] Non-amine based analogues of lavendustin A as protein-tyrosine kinase inhibitors. J Med Chem. 1993 Oct 1;36(20):3010-4.
• [23] Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2171-4.
• [24] Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
• [25] Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and prelimin... Bioorg Med Chem Lett. 2007 Apr 15;17(8):2305-9.
• [26] Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors. Bioorg Med Chem Lett. 2011 Oct 1;21(19):5870-5.
• [27] Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.
• [28] Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity. J Med Chem. 2006 Aug 10;49(16):4981-91.
• [29] Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60.